(189 days)
Not Found
No
The summary describes standard image processing techniques (registration, comparison, computation of parameter maps) and does not mention AI, ML, or related terms. The performance studies focus on technical validation and reproducibility, not on training or testing with large datasets typical of AI/ML models.
No.
GIQuant is a post-processing software that aids in advanced image assessment and monitoring of therapeutic response, but it does not directly provide therapy. It is designed to aid physicians in making treatment considerations, not to administer or deliver treatment itself.
Yes
The device is designed to "aid trained physicians in advanced image assessment, treatment consideration, and monitoring of therapeutic response," which are all aspects of diagnosing and managing a patient's condition. While it states that the information should not be used in isolation, its explicit purpose is to derive parameters from medical imaging to assist in clinical decision-making.
Yes
The device is explicitly described as a "standalone software medical imaging post processing application" that runs on "standard computer hardware." It performs analysis and generates outputs based on existing medical images, without including or requiring any specific hardware components beyond a standard computer.
Based on the provided information, GIQuant is NOT an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, tissue) to provide information for the diagnosis, treatment, or prevention of disease.
- GIQuant's Function: GIQuant processes medical images (MRI) obtained from the human body, specifically the abdomen. It performs numerical analysis and generates parameter maps based on these images. It does not analyze biological specimens.
- Intended Use: The intended use clearly states it's a post-processing software for existing medical imaging workflows to derive motion-related parameters from abdominal MRI data. It's designed to aid physicians in image assessment and treatment consideration, not to analyze biological samples.
Therefore, GIQuant falls under the category of medical imaging software, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
GIQuant is a post-processing software into existing medical imaging workflows that is intended to derive motion related parameters from abdominal data obtained during magnetic resonance imaging (MRI).
GIQuant is designed to aid trained physicians in advanced image assessment, treatment consideration, and monitoring of therapeutic response. The information provided by GIQuant should not be used in isolation when making patient management decisions.
Product codes
LLZ
Device Description
GIQuant is a standalone software medical imaging post processing application that runs on standard computer hardware. GIQuant performs numerical analysis and generates image parameter maps, based on DICOM images captured via Magnetic Resonance Imaging.
These actions include:
- . Receipt of MR DICOM image studies from DICOM storage and communication devices.
- .. Registration of images generated at different time points.
- . Comparison of registered images.
- Computation of motility parameter maps based on dynamic abdominal MR imaging data.
- . Output of the above maps in DICOM format for export to PACS.
GIQuant can be deployed within its own image storage and communication infrastructure or alternatively it can be "plugged in" and launched from within other FDA cleared applications.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Magnetic Resonance Imaging (MRI)
Anatomical Site
Abdominal
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Trained physicians (e.g Radiologist) in advanced image assessment, treatment consideration, and monitoring of therapeutic response.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Software verification and validation testing has been conducted and documentation provided as per the recommendations of FDA guidance, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" (May, 2005).
The software was developed in compliance with the requirements of IEC 62304:2006, ISO 14971:2019, and NEMA PS 3.1-3.20 (2016).
Software verification testing was conducted at a unit, integration and systems level to verify the implementation of functional requirements.
Technical performance assessment established the performance and suitability of GIQuant's algorithm in the context of shared questions with relation to safety and effectiveness. Methods utilized in performance testing included utilizing summary metrics obtained through region of interest placement on synthetically manipulated 'ground truth' datasets as well as measuring target registration error on a fixed point of anatomy when a region of interest propagated through a dataset is corrected by an expert user. Reproducibility was established through test-retest image data sets.
Software Validation testing was conducted to confirm the implementation of functional requirements within the context of a simulated real world use environment.
The tests results demonstrate that GIQuant functioned as intended, is acceptable for clinical use, and is safe and effective as its predicate device, without introducing new questions of safety and efficacy.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: on the left, there is a seal with an abstract image of a human figure, and on the right, there is the text "FDA U.S. FOOD & DRUG ADMINISTRATION" in blue. The text is arranged in three lines, with "FDA" in a larger font size than the rest of the text. The logo is clean and professional, and it is easily recognizable as the symbol of the FDA.
Motilent Ltd. % Ian Knott Head of Regulatory and Quality IDEALondon, 69 Wilson Street London, EC2A 2BB UNITED KINGDOM
November 8, 2021
Re: K211356
Trade/Device Name: GIQuant Regulation Number: 21 CFR 892.2050 Regulation Name: Medical image management and processing system Regulatory Class: Class II Product Code: LLZ Dated: September 7, 2021 Received: October 7, 2021
Dear Ian Knott:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For
Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known)
Device Name GIQuant
Indications for Use (Describe)
GIQuant is a post-processing software into existing medical imaging workflows that is intended to derive motion related parameters from abdominal data obtained during magnetic resonance imaging (MRJ).
GIQuant is designed to aid trained physicians in advanced image assessment, treatment consideration, and monitoring of therapeutic response. The information provided by GIQuant should not be used in isolation when making patient management decisions.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
==============================================================================================================================================================================
3
Image /page/3/Picture/1 description: The image shows the logo for Motilent. The logo features the word "Motilent" in a sans-serif font, with the "M" stylized as a blue, wavy line. There is a blue dot on the left side of the "M" and another blue dot on the right side of the "M".
Document Title:
5.0 GlQuant 510k - 510k summary
This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990.
1. Submitter:
- Motilent Ltd. IDEALondon, 69 Wilson Street, London, EC2A 2BB, United Kingdom
Contact Person: lan Knott Submitter, Holder and Owner Phone: +44 (0) 7817476978 E-mail: lan.Knott@motilent.co.uk
Date Summary Prepared: April 12, 2021
-
- Device:
| Device Name: | GIQuant |
|---|---|
| Device Common | |
| Name: | Radiological Image Processing Software |
| Regulation Number: | 21 CFR 892.2050 |
| Regulation name: | Medical image management and processing system |
| Device Classification: | Class II |
| Product code: | LLZ |
3. Predicate Device Information:
GIQuant is substantially equivalent to the following legally marketed devices that are currently cleared by the FDA:
| 510(k) reference | Device Name | Manufacturer | Clearance date |
|---|---|---|---|
| K123302 | IB Clinic v1.0 (clinic) | Imaging Biometrics, LLC | 11 January 2013 |
4
Image /page/4/Picture/0 description: The image shows the logo for Motilent. The logo features a stylized, light blue line that resembles a winding path or a digestive tract, with a small dot at the beginning and end. Below the graphic is the word "Motilent" in a dark blue, sans-serif font.
4. Device Description:
GIQuant is a standalone software medical imaging post processing application that runs on standard computer hardware. GIQuant performs numerical analysis and generates image parameter maps, based on DICOM images captured via Magnetic Resonance Imaging.
These actions include:
- . Receipt of MR DICOM image studies from DICOM storage and communication devices.
- .. Registration of images generated at different time points.
- . Comparison of registered images.
- 트 Computation of motility parameter maps based on dynamic abdominal MR imaging data.
- . Output of the above maps in DICOM format for export to PACS.
GIQuant can be deployed within its own image storage and communication infrastructure or alternatively it can be "plugged in" and launched from within other FDA cleared applications.
5. Indications for Use:
GIQuant is a post-processing software integrated into existing medical imaging workflows that is intended to derive motion related parameters from abdominal data obtained during magnetic resonance imaging (MRI).
GIQuant is designed to aid trained physicians in advanced image assessment, treatment consideration, and monitoring of therapeutic response. The information provided by GlQuant should not be used in isolation when making patient management decisions.
6. Comparison of Technological Characteristics with the predicate device
The intended use and performance characteristics for the subject device are substantially equivalent to the predicate device listed in section 3 above as both devices are intended for image analysis, image processing and generation of parametric maps to provide additional information beyond standard imaging.
| Subject Device | Predicate device | |
|---|---|---|
| Device Name | GIQuant | IB Clinic v1.0 (clinic) |
| 510(k) Clearance number | N/A | K123302 |
| Common Name | Radiological Image Processing Software | Radiological Image Processing Software |
| Regulation Number: | 892.2050 | 892.2050 |
| Regulation Name | Medical image management and processing system | Medical image management and processing system |
| Product code | LLZ | LLZ |
| Indications for use: | GIQuant is a post-processing software integrated into existing medical imaging workflows that is intended to derive motion related parameters from abdominal data | IB Clinic v1.0 (Clinic) is a post-processing software toolkit designed to be integrated into existing medical image visualization applications running on standard computer hardware. Clinic accepts relevant DICOM |
| obtained during magnetic resonance imaging (MRI). | ||
| GIQuant is designed to aid trained physicians in advanced image assessment, treatment consideration, and monitoring of therapeutic response. The information provided by GIQuant should not be used in isolation when making patient management decisions. | image sets, such as dynamic perfusion and diffusion image sets. Clinic generates various perfusion- and diffusion-related parameters, standardized image sets, and image intensity differences. The results are saved to a DICOM image file and may be further visualized on an imaging workstation. | |
| Clinic is designed to aid trained physicians in advanced image assessment, treatment consideration, and monitoring of therapeutic response. The information provided by Clinic should not be used in isolation when making patient management decisions. | ||
| Standalone Software | Yes | Yes |
| Energy Sources | N/A | N/A |
| Operates on off-the-shelf hardware | Yes | Yes |
| Standard windowing user interface | yes | yes |
| Post processing | yes | yes |
| Conforms to DICOM standards (PS 3.10) | yes | yes |
| Input data - Processes MR data | Yes | Yes |
| Input data - Abdominal Imaging | Yes | Yes |
| Input data - Imaging Modality | MR | MR and CT |
| Input data - Compatible MRI systems | All approved MRI systems generating DICOM compliant images | All approved MRI systems generating DICOM compliant images |
| Input data - Imaging Acquisition Protocol* | Dynamic 'cine' MR imaging, combination of T1 and T2 weighted images | Dynamic T1 and T2 weighted images |
| Input data - Data format | DICOM | DICOM |
| Transformation Segmentation | Whole image registration | Whole image registration |
| Transformation Registration | Non-rigid registration to align image features in time series data | |
| Registration of 2d image data | ||
| Registration applied on raw image data | Non-rigid registration to align image features in time series data | |
| Registration of 2d image data | ||
| Registration applied on raw image data | ||
| Transformation Parameterization* | Derived from image registration deformation fields represented as the SD Jacobian | Derived from variations in intensity over time |
| Output data -Results generation | Parametric map | Parametric map |
| Output data -Spatial localisation | 1:1 anatomical mapping | 1:1 anatomical mapping |
| Output data -File format | DICOM | DICOM |
| Output data -Summary metrics | Summary metrics can be obtained to quantify movement within a region of interest | Summary metrics can be obtained to quantify changes in intensity over time within a region of interest |
| Output data- Networking | Exported to PACS and/or OS file storage | Exported to PACS and/or OS file storage |
| Reporting - Intended user | Result interpreted by trained user (e.g Radiologist) | Result interpreted by trained user (e.g Radiologist) |
| Reporting - Viewing | Results can be viewed on DICOM compatible PACS viewer | Results can be viewed on DICOM compatible PACS viewer |
| Reporting - Availability of data | Original data available for viewing with output | Original data available for viewing with output |
A table comparing the key features of the subject and predicate device is provided below.
5
Image /page/5/Picture/0 description: The image shows the logo for Motilent. The logo features a stylized, light blue, curvy line that resembles a simplified representation of the digestive system. The word "Motilent" is written in a dark blue sans-serif font below the graphic. The logo is clean and modern.
6
Image /page/6/Picture/0 description: The image features the logo for Motilent. The logo consists of a stylized, light blue graphic resembling a connected series of curves, with a small dot at the beginning and end of the curves. Below the graphic, the word "Motilent" is written in a dark blue, sans-serif font.
- As evidenced from the table above, the subject and predicate device share the same core technological functionality however minor differences exist between the two devices under review. These differences are not considered to raise different questions with relation to safety and effectiveness and have been evaluated through performance testing.
7. Performance Data:
Software verification and validation testing has been conducted and documentation provided as per the recommendations of FDA guidance, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" (May, 2005).
The software was developed in compliance with the requirements of IEC 62304:2006, ISO 14971:2019, and NEMA PS 3.1-3.20 (2016).
Software verification testing
Software verification testing was conducted at a unit, integration and systems level to verify the implementation of functional requirements.
Technical Performance testing
Technical performance assessment established the performance and suitability of GlQuant's algorithm in the context of shared questions with relation to safety and effectiveness. Methods utilized in performance testing included utilizing summary metrics obtained through region of interest placement on synthetically manipulated 'ground truth' datasets as well as measuring target registration error on a fixed point of anatomy when a region of interest propagated through a dataset is corrected by an expert user. Reproducibility was established through test-retest image data sets.
Validation Testing
Software Validation testing was conducted to confirm the implementation of functional requirements within the context of a simulated real world use environment.
The tests results demonstrate that GlQuant functioned as intended, is acceptable for clinical use, and is safe and effective as its predicate device, without introducing new questions of safety and efficacy.
8. Conclusion:
GIQuant shares the same intended use as the cited predicate device. Verification and validation testing performed demonstrates that GlQuant performs as intended in the specified use condition. Technical performance data shows that, where technological differences are apparent, GlQuant performs to a suitable level to address shared questions with relation to safety and effectiveness. It can therefore be concluded that GIQuant is substantially equivalent to the predicate device.
Declarations:
- This summary includes only information that is also covered in the body of the 510(k).
- This summary does not contain any puffery or unsubstantiated labelling claims.
- This summary does not contain any raw data, i.e., contains only summary data.
- This summary does not contain any trade secret or confidential commercial information.
- This summary does not contain any patient identification information.